Evaluation of 18F-X12 for Diagnosis of Hepatocellular Carcinoma (HCC)

This clinical study focuses on a new diagnostic approach for hepatocellular carcinoma (HCC), a type of liver cancer. The study is evaluating a novel radiotracer, known as 18F-X12, which is designed to target a specific protein called Glypican-3 (GPC3) often found in HCC. The goal is to determine if this new method can help in early diagnosis, accurate staging, and assessment of cancer recurrence in patients with HCC. This research is important as it could potentially improve the way HCC is detected and managed, addressing current challenges in liver cancer care. During the study, participants with HCC will undergo a procedure called positron emission tomography (PET) imaging using the 18F-X12 radiotracer. This involves an injection of the radiotracer, followed by a scan to see how it interacts with the body. The study will measure the diagnostic efficacy of this method by comparing the results with histopathological findings, which are the current gold standard for diagnosis. Additionally, the safety and tolerability of 18F-X12 will be monitored, with any adverse events such as fever, rash, or hypoglycemia recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 6.0).